Key clinical point: Preoperative nivolumab plus ipilimumab appears safe and active in patients with early-stage colon cancer.
Major finding: Pathological responses occurred in 100% of patients with mismatch repair–deficient tumors and in 27% of patients with mismatch repair–proficient tumors. Grade 3-4 treatment‐related adverse events were reported in 13% of patients.
Study details: A phase 2 trial of 40 patients with resectable, early-stage colon adenocarcinoma.
Disclosures: The study was sponsored by the Netherlands Cancer Institute in collaboration with Bristol-Myers Squibb. Authors reported financial relationships with Bristol-Myers Squibb and many other companies.
Chalabi M et al. Nat Med. 2020 Apr 6. doi: 10.1038/s41591-020-0805-8.